Relay Therapeutics, Inc. (RLAY)
$17.88+2.70%Close
SELLRECOVERY · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.1B
- Beta
- 1.73
- P/E (TTM)
- -11.94
- Short % float
- 34.34%
- Days to cover
- 12.6
- SI change
- +5.1%
- 1W
- -5.70%
- 1M
- -5.35%
- vs SPY 1W
- -6.86%
- vs SPY 1M
- -8.34%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$42.5BRECOVERYQ 30$199.87+0.87%
- KYMRSELLKymera Therapeutics, Inc.$8.7BBEARQ 25$105.98+2.84%
- ERASSELLErasca, Inc.$5.0BRECOVERYQ 4$14.30+3.69%
- TNGXSELLTango Therapeutics, Inc.$3.6BRECOVERYQ 24$21.90+5.49%
- IDYASELLIDEAYA Biosciences, Inc.$3.5BBEARQ 25$36.63+0.14%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.60+0.63%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.98-0.33%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$20.24-0.15%
- AVBPSELLArriVent BioPharma, Inc.$703MCRISISQ -5$15.09+0.12%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RLAY?
- LOPJLB’s latest quantitative signal on Relay Therapeutics, Inc. (RLAY) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is RLAY in?
- Relay Therapeutics, Inc. (RLAY) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Relay Therapeutics, Inc. (RLAY) do?
- Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administere…